Published Date: 07 Jun 2024
Enhancing quality of life was another benefit of anticholinergic oxybutynin for ADT-using patients.
Read Full News5 Psychiatry Headlines You Missed in September 2026
An updated open-label extension analysis and new MRI data from the phase 3 EPIDYS trial, presented at the 2026 AANEM Annual Meeting, add to the evidence for givinostat's long-term effects on disease progression.
A new Bayesian network meta-analysis found nipocalimab's serious adverse event rates compared favorably with other gMG therapies, while overall adverse event rates were comparable.
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of MDS!
Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis
Friedman outlines how dermatologists can track cumulative corticosteroid exposure, identify at-risk patients, and improve patient adherence with handouts.
1.
Increased anti-tumor response and reduced side effects from immune checkpoint inhibitors.
2.
Underprescribed for Alcohol Use Disorder is pharmacotherapy.
3.
In early dementia, SSRIs enhance cognition and major depression.
4.
Asymptomatic or Minimally Symptomatic Myelofibrosis
5.
Physician Fights Insurer to Cover Her Baby's Brain Cancer Treatment
1.
Comprehensive Techniques in Hematology in Clinical Decision-Making
2.
Unveiling the Hidden Causes of Anemia: A Comprehensive Look at a Common Condition
3.
Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy
4.
Ferroptosis-Modulating Nanocarriers for Solid Tumor Therapy
5.
Exploring the Potential of Xospata: A New Frontier in Cancer Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation